The impact of ultraviolet- and infrared-based laser microdissection technology on phosphoprotein detection in the laser microdissection-reverse phase protein array workflow.
Laser capture microdissection
Laser microdissection
Phosphoprotein
Proteomics
Reverse phase protein array
Journal
Clinical proteomics
ISSN: 1542-6416
Titre abrégé: Clin Proteomics
Pays: England
ID NLM: 101184586
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
09
2019
accepted:
20
02
2020
entrez:
14
3
2020
pubmed:
14
3
2020
medline:
14
3
2020
Statut:
epublish
Résumé
Reversible protein phosphorylation represents a key mechanism by which signals are transduced in eukaryotic cells. Dysregulated phosphorylation is also a hallmark of carcinogenesis and represents key drug targets in the precision medicine space. Thus, methods that preserve phosphoprotein integrity in the context of clinical tissue analyses are crucially important in cancer research. Here we investigated the impact of UV laser microdissection (UV LMD) and IR laser capture microdissection (IR LCM) on phosphoprotein abundance of key cancer signaling protein targets assessed by reverse-phase protein microarray (RPPA). Tumor epithelial cells from consecutive thin sections obtained from four high-grade serous ovarian cancers were harvested using either UV LMD or IR LCM methods. Phosphoprotein abundances for ten phosphoproteins that represent important drug targets were assessed by RPPA and revealed no significant differences in phosphoprotein integrity from those obtained using higher-energy UV versus the lower-energy IR laser methods.
Identifiants
pubmed: 32165870
doi: 10.1186/s12014-020-09272-z
pii: 9272
pmc: PMC7061469
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsTPC receives research funding from AbbVie. EFP receives research funding from Genentech, Pfizer, AbbVie, and is a co-inventor of the RPPA technology described herein and receives royalties on the related license agreements.
Références
Clin Pharmacol Ther. 2017 May;101(5):619-621
pubmed: 28187513
N Engl J Med. 2010 Oct 14;363(16):1532-43
pubmed: 20942669
Neoplasia. 2017 Feb;19(2):100-111
pubmed: 28088687
Mol Carcinog. 2016 Nov;55(11):1688-1699
pubmed: 26457987
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10516-21
pubmed: 22689991
Mod Pathol. 2010 Mar;23(3):404-12
pubmed: 20062014
Methods Mol Biol. 2011;785:23-43
pubmed: 21901591
Clin Pharmacol Ther. 2019 Jul;106(1):52-57
pubmed: 30838639
Yale J Biol Med. 2006 Dec;79(3-4):153-63
pubmed: 17940625
J Proteome Res. 2014 Jun 6;13(6):2846-55
pubmed: 24787230
Scand J Gastroenterol. 2009;44(7):787-95
pubmed: 19391063
Am J Pathol. 2010 Oct;177(4):1611-7
pubmed: 20802181
Clin Cancer Res. 2012 Dec 1;18(23):6426-35
pubmed: 23045247
Am J Pathol. 1997 Jul;151(1):63-7
pubmed: 9212732
Nature. 2006 Jan 19;439(7074):353-7
pubmed: 16273092
Clin Cancer Res. 2017 Aug 15;23(16):4919-4928
pubmed: 28446508
Eur J Cancer. 2015 Sep;51(13):1831-42
pubmed: 26059197
Clin Cancer Res. 2016 Sep 15;22(18):4556-8
pubmed: 27199492
PLoS One. 2011;6(8):e23780
pubmed: 21858221
Neoplasia. 2009 Feb;11(2):126-35
pubmed: 19177197
Forensic Sci Int. 2007 Jan 17;165(2-3):150-4
pubmed: 16806766
Methods Mol Biol. 2005;293:151-66
pubmed: 16028418
Mol Cell Proteomics. 2008 Oct;7(10):1998-2018
pubmed: 18667411
Cell Mol Biol (Noisy-le-grand). 1998 Jul;44(5):735-46
pubmed: 9764744
Drug Discov Today. 2005 Sep 1;10(17):1175-82
pubmed: 16182210
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1229-35
pubmed: 22810955
Genet Anal. 1997 Mar;14(1):1-8
pubmed: 9158958
BMC Cancer. 2017 Jun 17;17(1):422
pubmed: 28623900
Front Oncol. 2014 Nov 26;4:339
pubmed: 25505737
Cancer Res. 2008 Jul 15;68(14):6014-20
pubmed: 18632658
Sci Rep. 2017 Sep 4;7(1):10374
pubmed: 28871211
Proteomics Clin Appl. 2015 Oct;9(9-10):928-37
pubmed: 25676683
Cancer. 2017 Oct 15;123(20):4004-4012
pubmed: 28654152
Lab Invest. 2010 May;90(5):787-96
pubmed: 20195244
Proteomes. 2013 Oct 17;1(3):240-253
pubmed: 28250404
Gynecol Oncol. 2018 Apr;149(1):106-116
pubmed: 29605044
Mol Oncol. 2010 Dec;4(6):482-95
pubmed: 20937571
Proteomics Clin Appl. 2009 May 5;3(5):516-527
pubmed: 19834583
J Pathol. 2018 Apr;244(5):628-637
pubmed: 29344964
PLoS One. 2013;8(3):e58226
pubmed: 23554878
Microsc Res Tech. 2009 Dec;72(12):908-12
pubmed: 19425073
Anal Biochem. 2013 Aug 15;439(2):88-98
pubmed: 23643622
Methods Inf Med. 2006;45(5):557-63
pubmed: 17019511
Science. 1996 Nov 8;274(5289):998-1001
pubmed: 8875945
J Biomol Tech. 2002 Dec;13(4):258-64
pubmed: 19498991
Front Oncol. 2016 Oct 27;6:213
pubmed: 27833898
BMC Genomics. 2006 Apr 27;7:97
pubmed: 16643667
J Biomol Tech. 2010 Apr;21(1):25-8
pubmed: 20357979
Rapid Commun Mass Spectrom. 2017 Jan 30;31(2):171-178
pubmed: 27794190
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Science. 1997 Nov 21;278(5342):1481,1483
pubmed: 9411767
Br J Cancer. 2004 Aug 16;91(4):725-31
pubmed: 15305183
Br J Cancer. 2017 Aug 8;117(4):494-502
pubmed: 28664915
J Proteome Res. 2008 Apr;7(4):1508-17
pubmed: 18257519
Cancer. 2010 Nov 15;116(22):5261-71
pubmed: 20665887
Clin Cancer Res. 2012 Feb 1;18(3):869-81
pubmed: 22142828
Geburtshilfe Frauenheilkd. 2017 Oct;77(10):1095-1103
pubmed: 29093603
BMC Cancer. 2008 Oct 24;8:308
pubmed: 18950492
Cancer Res. 2014 Feb 1;74(3):818-28
pubmed: 24346432
Oncotarget. 2015 Dec 29;6(42):44551-62
pubmed: 26575166
PLoS One. 2014 Sep 29;9(9):e108046
pubmed: 25265318
Forensic Sci Int. 2005 Oct 29;153(2-3):174-80
pubmed: 16139107
Proteomics. 2015 Jan;15(2-3):365-73
pubmed: 25311472
Gynecol Oncol. 2015 Apr;137(1):173-9
pubmed: 25677064
Biotechniques. 1999 Aug;27(2):362-7
pubmed: 10457845